ARN14974
(Synonyms: Acid Ceramidase Inhibitor 17a) 目录号 : GC13263
An inhibitor of acid ceramidase
Cas No.:1644158-57-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 79 nM
ARN14974 is an acid ceramidase inhibitor.
The ceramides, a family of bioactive lipid-derived messengers, are involved in the control of cellular senescence, inflammation, as well as apoptosis. Ceramide hydrolysis by acid ceramidase (AC) can stop the biological activity of these substances and influence survival and function of normal and neoplastic cells.
In vitro: In a previous study, human colon adenocarcinoma SW403 cells and mouse macrophage-like Raw 264.7 cells were incubated in the presence of ARN14974. Results showed that ARN14974 could inhibit cellular AC activity with an IC50 of 825 nm in SW403 and 400 nm in Raw 264.7 cells. Moreover, consistent with these results, incubation with ARN14974 led to an increase in the levels of ceramide and a corresponding decrease in the levels of sphingosine [1].
In vivo: Injection of ARN14974 in mice was able to cause a substantial reduction in AC activity in multiple organs, including heart, lungs, brain, liver, and kidney. Highest levels of baseline AC activity and AC inhibition were found in lung tissue. As expected, the authors found a significant increase in ceramide species. Moreover, the levels of ceramides with longer fatty acyl chains were not affected. Furthermore, ARN14974 appeared to be well tolerated at the dosage tested [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] D. Pizzirani, A. Bach, N. Realini, et al. Benzoxazolone carboxamides: Potent and systemically active inhibitors of intracellular acid ceramidase. Angewandte Chemistry International Edition English 54(2), 485-489 (2014).
| Cas No. | 1644158-57-5 | SDF | |
| 别名 | Acid Ceramidase Inhibitor 17a | ||
| 化学名 | 6-(4-fluorophenyl)-2-oxo-N-(4-phenylbutyl)-3(2H)-benzoxazolecarboxamide | ||
| Canonical SMILES | FC(C=C1)=CC=C1C2=CC=C3C(OC(N3C(NCCCCC4=CC=CC=C4)=O)=O)=C2 | ||
| 分子式 | C24H21FN2O3 | 分子量 | 404.4 |
| 溶解度 | ≤2mg/ml in DMSO;2mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4728 mL | 12.364 mL | 24.728 mL |
| 5 mM | 0.4946 mL | 2.4728 mL | 4.9456 mL |
| 10 mM | 0.2473 mL | 1.2364 mL | 2.4728 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。